Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

AZD2693

Oligonucleotide (Antisense oligonucleotide) · developed by ASTRAZENECA

Phase 2 Most advanced trial (none active)
AZN Developer

What is AZD2693?

AZD2693 is a subcutaneously administered solution studied in nonalcoholic steatohepatitis, a liver disease related to nonalcoholic fatty liver disease and liver cirrhosis.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Oligonucleotide (Antisense oligonucleotide)
Therapy area
Gastroenterology
Developer
ASTRAZENECA (AZN)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 2

Conditions studied

Nonalcoholic Steatohepatitis

More from ASTRAZENECA

Sources

Updated Nov 1, 2026. Something wrong or missing? Report it on the AZN page.

Follow AZN, the company behind AZD2693

See AZN's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

AZN catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.